{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:08:39Z","timestamp":1772168919174,"version":"3.50.1"},"update-to":[{"DOI":"10.12688\/f1000research.147794.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000}}],"reference-count":47,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","award":["1235463-HFST-P"],"award-info":[{"award-number":["1235463-HFST-P"]}],"id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>Introduction Carriers of variant alleles of genes that encode liver CYP450 and UGT enzymes may experience abnormal plasma levels of antipsychotics and, consequently, worse efficacy or tolerability. Although pharmacogenomics is a rapidly developing field, current guidelines often rely on limited, underpowered evidence. We have previously demonstrated that meta-analysis is a viable strategy for overcoming this problem. Here, we propose a project that will expand our previous work and create a living systematic review and meta-analysis of drug plasma level differences between carriers and non-carriers of variant genotype-predicted phenotypes for every pharmacokinetic drug-gene interaction relevant to commonly used antipsychotic drugs. Protocol First, a baseline systematic review and meta-analysis will be conducted by searching for observational pharmacogenomics-pharmacokinetic studies. Data on dose-adjusted drug plasma levels will be extracted, and participants will be grouped based on their genotype for each drug-gene pair separately. Differences in plasma drug levels between different phenotypes will be compared using a random-effect ratio-of-means meta-analysis. The risk of bias will be assessed using ROBINS-I, and the certainty of evidence will be assessed using GRADE. Following the establishment of baseline results, the literature search will be re-run at least once every six months, and the baseline data will be updated and re-evaluated as new evidence is published. A freely available website will be designated to present up-to-date results and conclusions. Discussion This systematic review will provide evidence-based results that are continuously updated with evidence as it emerges in the rapidly developing field of pharmacogenomics. These results may help psychiatrists in their decision-making, as clinicians are becoming increasingly aware of the patients\u2019 genetic data as testing becomes more widespread and cheaper. In addition, the results may serve as a scientific basis for the development of evidence-based pharmacogenomics algorithms for personalized dosing of antipsychotics to mitigate potentially harmful drug-gene interactions.<\/ns3:p>","DOI":"10.12688\/f1000research.147794.2","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T10:48:40Z","timestamp":1720694920000},"page":"452","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Living systematic review and meta-analysis of plasma-concentrations of antipsychotic drugs in carriers and non-carriers of variant CYP450 genotypes: Living systematic review protocol"],"prefix":"10.12688","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6532-4661","authenticated-orcid":false,"given":"Filip","family":"Milosavljevi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-4352","authenticated-orcid":false,"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"68-75","DOI":"10.1038\/s41380-022-01887-y","article-title":"Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies.","volume":"28","author":"A Miller","year":"Jan 2023","journal-title":"Mol. Psychiatry."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"58-72","DOI":"10.1038\/s41380-021-01200-3","article-title":"Treatment resistance in psychiatry: state of the art and new directions.","volume":"27","author":"O Howes","year":"Jan 2022","journal-title":"Mol. Psychiatry."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"33-37","DOI":"10.1136\/eb-2014-101813","article-title":"Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective.","volume":"17","author":"M Dold","year":"May 2014","journal-title":"Evid. Based Ment. Health."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology.","volume":"172","author":"S Kaar","year":"Aug 1 2020","journal-title":"Neuropharmacology."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184275","article-title":"Review: Influence of the CYP450 Genetic Variation on the Treatment of Psychotic Disorders.","volume":"10","author":"L Carrascal-Laso","year":"Sep 21 2021","journal-title":"J. Clin. Med."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"9-62","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.","volume":"51","author":"C Hiemke","year":"Jan 2018","journal-title":"Pharmacopsychiatry."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"410-8","DOI":"10.2174\/138920008784746373","article-title":"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.","volume":"9","author":"L Urichuk","year":"Jun 2008","journal-title":"Curr. Drug Metab."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"496-526","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.","volume":"116","author":"M Ingelman-Sundberg","year":"Dec 2007","journal-title":"Pharmacol. Ther."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"542-545","DOI":"10.1002\/cpt.2321","article-title":"Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation.","volume":"110","author":"A Gaedigk","year":"Sep 2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"278-285","DOI":"10.1038\/s41431-023-01347-3","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.","volume":"32","author":"L Beunk","year":"Mar 2024","journal-title":"Eur. J. Hum. Genet."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"214-222","DOI":"10.1097\/FPC.0000000000000347","article-title":"PharmGKB summary: clozapine pathway, pharmacokinetics.","volume":"28","author":"C Thorn","year":"Sep 2018","journal-title":"Pharmacogenet. Genomics."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"563-572","DOI":"10.1002\/cpt.2350","article-title":"An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine.","volume":"110","author":"M Whirl-Carrillo","year":"Sep 2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"92-116","DOI":"10.1016\/j.pharmthera.2013.09.002","article-title":"Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.","volume":"141","author":"J Stingl","year":"Jan 2014","journal-title":"Pharmacol. Ther."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"369-396","DOI":"10.1080\/17425255.2021.1876661","article-title":"ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?","volume":"17","author":"H Bruckmueller","year":"Apr 3 2021","journal-title":"Expert Opin. Drug Met."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1827-1835","DOI":"10.1111\/bcp.14288","article-title":"Association between 8 P-glycoprotein (MDR1\/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia.","volume":"86","author":"L Geers","year":"Sep 2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"270-280","DOI":"10.1001\/jamapsychiatry.2020.3643","article-title":"Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.","volume":"78","author":"F Milosavljevic","year":"Mar 1 2021","journal-title":"JAMA Psychiatry."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1055-1069","DOI":"10.1016\/j.tips.2022.09.011","article-title":"Pharmacogenomics in treatment of depression and psychosis: an update.","volume":"43","author":"M Jukic","year":"Dec 2022","journal-title":"Trends Pharmacol. Sci."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1240-1255","DOI":"10.1002\/cpt.1720","article-title":"Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements.","volume":"107","author":"R Shekhani","year":"May 2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.","volume":"349","author":"L Shamseer","year":"Jan 2 2015","journal-title":"BMJ."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2008-2012","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.","volume":"283","author":"D Stroup","year":"Apr 19 2000","journal-title":"JAMA."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"896-907","DOI":"10.1177\/0269881110389208","article-title":"Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study.","volume":"25","author":"G Nikisch","year":"Jul 2011","journal-title":"J .Psychopharmacol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"926-932","DOI":"10.3109\/00498254.2014.901585","article-title":"Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole.","volume":"44","author":"Y Nagasaka","year":"Oct 2014","journal-title":"Xenobiotica."},{"key":"ref24","first-page":"80-88","article-title":"The Pharmacokinetics of Paliperidone Versus Risperidone.","volume":"51","author":"J Leon","year":"Jan-Feb 2010","journal-title":"Psychosomatics."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1-13","DOI":"10.1002\/hup.320","article-title":"A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers.","volume":"17","author":"P Rosenzweig","year":"Jan 2002","journal-title":"Hum. Psychopharmacol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"229-232","DOI":"10.1097\/01.jcp.0000084028.22282.f2","article-title":"Ziprasidone metabolism, aldehyde oxidase, and clinical implications.","volume":"23","author":"C Beedham","year":"Jun 2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"9-18","DOI":"10.1080\/00498254.2019.1648911","article-title":"Cytochrome P450: genotype to phenotype.","volume":"50","author":"R Waring","year":"Jan 2020","journal-title":"Xenobiotica."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"222-40","DOI":"10.1111\/bcp.12441","article-title":"Addressing phenoconversion: the Achilles\u2019 heel of personalized medicine.","volume":"79","author":"R Shah","year":"Feb 2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1493-1528","DOI":"10.1007\/s40262-018-0664-3","article-title":"Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.","volume":"57","author":"M Mauri","year":"Dec 2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"417-423","DOI":"10.1007\/s40265-020-01271-6","article-title":"Lumateperone: First Approval.","volume":"80","author":"H Blair","year":"Mar 2020","journal-title":"Drugs."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"563-569","DOI":"10.1007\/BF00315316","article-title":"Pharmacokinetics of chlorpromazine and key metabolites.","volume":"45","author":"P Yeung","year":"1993","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"16-19","DOI":"10.1007\/BF00431770","article-title":"Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice.","volume":"87","author":"L Hansen","year":"1985","journal-title":"Psychopharmacology (Berl)."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range.","volume":"14","author":"X Wan","year":"Dec 19 2014","journal-title":"BMC Med. Res. Methodol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1139-1144","DOI":"10.2217\/pgs-2020-0115","article-title":"CYP2D6 pharmacogenetics and risperidone: reflections after 25 years of research.","volume":"21","author":"J Leon","year":"Nov 2020","journal-title":"Pharmacogenomics."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"688-700","DOI":"10.1002\/cpt.690","article-title":"Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.","volume":"102","author":"Y Zhou","year":"Oct 2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"7-10","DOI":"10.1055\/s-0028-1100908","article-title":"Study types and bias-Don\u2019t judge a study by the abstract\u2019s conclusion alone.","volume":"1","author":"D Norvell","year":"Aug 2010","journal-title":"Evid. Based Spine Care J."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"J Sterne","year":"Oct 12 2016","journal-title":"BMJ."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"M Page","year":"Mar 29 2021","journal-title":"BMJ."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"753-754","DOI":"10.2105\/Ajph.2020.305609","article-title":"Cochrane Handbook for Systematic Reviews of Interventions.","volume":"110","author":"M Nasser","year":"Jun 2020","journal-title":"Am. J. Public Health."},{"key":"ref42","article-title":"WebPlotDigitizer 4.6.","author":"A Rohatgi","year":"2022"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-2288-8-32","article-title":"The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: A simulation study.","volume":"8","author":"J Friedrich","year":"May 21 2008","journal-title":"BMC Med. Res. Methodol."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.","volume":"343","author":"J Sterne","year":"Jul 22 2011","journal-title":"BMJ."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"629-634","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"M Egger","year":"Sep 13 1997","journal-title":"BMJ."},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10040289","article-title":"Application of a Pharmacogenetics-Based Precision Medicine Model (5SPM) to Psychotic Patients That Presented Poor Response to Neuroleptic Therapy.","volume":"10","author":"L Carrascal-Laso","year":"Dec 2020","journal-title":"J. Pers. Med."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e2027909","DOI":"10.1001\/jamanetworkopen.2020.27909","article-title":"Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial.","volume":"3","author":"G Jurgens","year":"Dec 1 2020","journal-title":"JAMA Netw. Open."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e2335518","DOI":"10.1001\/jamanetworkopen.2023.35518","article-title":"Multigenetic Pharmacogenomics-Guided Treatment vs Treatment As Usual Among Hospitalized Men With Schizophrenia.","volume":"6","author":"Z Kang","year":"Oct 6 2023","journal-title":"JAMA Netw. Open."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"208-209","DOI":"10.1016\/j.jpsychires.2019.04.002","article-title":"Letter to the Editor: Clinical versus statistical significance of pharmacogenomic-guided antidepressant therapy: What\u2019s really being measured and marketed?.","volume":"114","author":"J Goldberg","year":"Jul 2019","journal-title":"J. Psychiatr. Res."},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.25109675.v2","article-title":"Living CYP - Extended data - F1000 25mar2024.docx.","author":"F Milosavljevi\u0107","year":"2024","journal-title":"figshare."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/13-452\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/13-452\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/13-452\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:25:15Z","timestamp":1722385515000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/13-452\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":47,"URL":"https:\/\/doi.org\/10.12688\/f1000research.147794.2","relation":{"has-version":[{"id-type":"doi","id":"10.12688\/f1000research.147794.1","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.168742.r300641","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.168742.r300642","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.168742.r300641","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.168742.r300642","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/13-452\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.168742.r300642, Jhohann Richard de Lima Benzi, University of S\u00e3o Paulo, S\u00e3o Paulo, 16 Jul 2024, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/13-452\/v2#referee-response-300642","order":0,"name":"referee-response-300642","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.168742.r300641, Pierre Baumann, Department of Psychiatry (DP-CHUV), Universite de Lausanne, Lausanne, Vaud, 31 Jul 2024, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/13-452\/v2#referee-response-300641","order":1,"name":"referee-response-300641","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work was supported by Alexander von Humboldt Foundation\u2019s Postdoctoral Fellowship Stipend (awarded to FM, stipend number: 1235463-HFST-P). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}